A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.
An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.
1 other identifier
interventional
12
1 country
1
Brief Summary
The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1 healthy
Started Apr 2009
Shorter than P25 for phase_1 healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 5, 2009
CompletedFirst Posted
Study publicly available on registry
March 6, 2009
CompletedStudy Start
First participant enrolled
April 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2009
CompletedDecember 7, 2018
December 1, 2018
1 month
March 5, 2009
December 5, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pharmacokinetics: Cmax, AUCinf
June - July 2009
Secondary Outcomes (1)
Tmax, Tlag, AUClast, AUCt, t½, Frel.
June-July 2009
Study Arms (2)
Suspension
EXPERIMENTALPF-02413873 suspension
Tablet
EXPERIMENTALPF-02413873 Phase 2 Tablets
Interventions
Eligibility Criteria
You may qualify if:
- Healthy male and female volunteers.
- Female volunteers have to be of non-childbearing potential
You may not qualify if:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (1)
Pfizer Investigational Site
Singapore, 188770, Singapore
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 5, 2009
First Posted
March 6, 2009
Study Start
April 1, 2009
Primary Completion
May 1, 2009
Study Completion
May 1, 2009
Last Updated
December 7, 2018
Record last verified: 2018-12